The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
In this video, James Essell, MD, Oncology Hematology Care, Inc., Cincinnati, OH, discusses the potential to implement a novel smartphone-based remote therapeutic monitoring system in community practices to facilitate the prompt identification of cytokine release syndrome (CRS) and other toxicities following outpatient administration of bispecific T-cell engagers. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
